Trials / Completed
CompletedNCT02233959
Palatability of a Novel Oral Formulation of Prednsione
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- Arkansas Children's Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 32 Years
- Healthy volunteers
- Accepted
Summary
Prednisone solution USP (5mg/5mL), is the most commonly prescribed formulation of prednisone to pediatric and adult patients. The rationale for this study is that palatability is the most important determinant of pediatric patient compliance, and therefore, it is critical that the Orbis formulation be perceived as significantly more palatable compared to today's commercially available products in order to warrant further development of the TP.
Conditions
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2015-12-01
- Completion
- 2016-01-01
- First posted
- 2014-09-09
- Last updated
- 2016-02-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02233959. Inclusion in this directory is not an endorsement.